Jeffrey Stuart Peters - 05 Feb 2024 Form 4 Insider Report for MACROGENICS INC (MGNX)

Signature
/s/ Lynn M. Cilinski, Attorney-in-fact
Issuer symbol
MGNX
Transactions as of
05 Feb 2024
Net transactions value
-$410,786
Form type
4
Filing time
07 Feb 2024, 16:17:12 UTC
Previous filing
14 Mar 2023
Next filing
12 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise $625,324 +54,376 $11.50 54,376 05 Feb 2024 Direct
transaction MGNX Common Stock Options Exercise $222,031 +21,875 +40% $10.15 76,251 05 Feb 2024 Direct
transaction MGNX Common Stock Sale $897,204 -54,376 -71% $16.50 21,875 05 Feb 2024 Direct F1
transaction MGNX Common Stock Sale $360,938 -21,875 -100% $16.50 0 05 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee stock option (right to buy) Options Exercise $0 -54,376 -83% $0.000000 10,875 05 Feb 2024 Common Stock 54,376 $11.50 Direct F2
transaction MGNX Employee stock option (right to buy) Options Exercise $0 -21,875 -31% $0.000000 48,125 05 Feb 2024 Common Stock 21,875 $10.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022.
F2 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.